

# 1 Enhancer profiling identifies epigenetic markers of 2 endocrine resistance and reveals therapeutic options for 3 metastatic castration-resistant prostate cancer patients

4  
5 Tesa M. Severson<sup>1,2,3,\*</sup>, Yanyun Zhu<sup>1,2,\*</sup>, Stefan Prekovic<sup>1,2,\*</sup>, Karianne Schuurman<sup>1</sup>, Holly M.  
6 Nguyen<sup>4</sup>, Lisha G. Brown<sup>4</sup>, Sini Hakkola<sup>5</sup>, Yongsoo Kim<sup>1,6</sup>, Jeroen Kneppers<sup>1,2</sup>, Simon  
7 Linder<sup>1,2</sup>, Suzan Stelloo<sup>1,2,7</sup>, Cor Liefstink<sup>3</sup>, Michiel van der Heijden<sup>3,8</sup>, Matti Nykter<sup>5</sup>, Vincent  
8 van der Noort<sup>9</sup>, Joyce Sanders<sup>10</sup>, Ben Morris<sup>3</sup>, Guido Jenster<sup>11</sup>, Geert JLH van Leenders<sup>12</sup>,  
9 Mark Pomerantz<sup>13</sup>, Matthew L. Freedman<sup>13,14</sup>, Roderick L. Beijersbergen<sup>3</sup>, Alfonso  
10 Urbanucci<sup>5,15</sup>, Lodewyk Wessels<sup>2,3,16</sup>, Eva Corey<sup>4</sup>, Wilbert Zwart<sup>1,2,17#</sup>, Andries M.  
11 Bergman<sup>1,8#</sup>  
12

13 **1** Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands

14 **2** Oncode Institute, Utrecht, the Netherlands

15 **3** Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the  
16 Netherlands

17 **4** Department of Urology, University of Washington, Seattle, WA, USA

18 **5** Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere  
19 University and Tays Cancer Centre, Tampere, Finland

20 **6** present working address: Department of Pathology, Cancer Center Amsterdam,  
21 Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

22 **7** present working address: Department of Molecular Biology, Faculty of Science, Radboud  
23 Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, 6525  
24 GA Nijmegen, the Netherlands.

25 **8** Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the  
26 Netherlands

27 **9** Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

28 **10** Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

29 **11** Department of Urology, Erasmus MC, Rotterdam, the Netherlands

30 **12** Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre,  
31 Rotterdam, the Netherlands.

32 **13** Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School,  
33 Boston, MA, USA.

34 **14** The Eli and Edythe L. Broad Institute, Cambridge, MA, USA

35 **15** Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital,  
36 Oslo, Norway

37 **16** Department of EEMCS, Delft University of Technology, Delft, the Netherlands.

38 **17** Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department  
39 of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the  
40 Netherlands.  
41

42 \*shared first authors

43 # corresponding authors: [w.zwart@nki.nl](mailto:w.zwart@nki.nl), [a.bergman@nki.nl](mailto:a.bergman@nki.nl)

44  
45  
46 **Keywords:** mCRPC, enzalutamide, epigenetics, androgen receptor, H3K27ac, HDAC  
47 inhibitors, biomarkers, hormone intervention

48

49 **Abstract**

50 Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options  
51 for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance  
52 inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we  
53 epigenetically profiled enhancer/promoter activities with H3K27ac chromatin  
54 immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We  
55 identified a distinct subset of H3K27ac-differentially marked regions that associated with  
56 treatment responsiveness. These data were successfully validated in mCRPC patient-  
57 derived xenograft models (PDX). *In silico* analyses revealed HDAC3 as a critical factor that  
58 can drive resistance to hormonal interventions, which we validated *in vitro*. Using cell lines  
59 and mCRPC PDX tumors *in vitro*, we identified drug-drug synergy between enzalutamide and  
60 the pan-HDAC inhibitor vorinostat, providing therapeutic proof-of-concept. These findings  
61 demonstrate rationale for new therapeutic strategies using a combination of AR and HDAC  
62 inhibitors to improve patient outcome in advanced stages of mCRPC.

63

64

65

66

67

68

69

70

71

72

73

## 74 **Background**

75 Prostate cancer is the most prevalent cancer type in men, with globally over 1.4 million new  
76 diagnoses and 375,000 patients who succumb to the disease each year<sup>1</sup>. Although most  
77 patients with high-risk localized disease are effectively treated with either prostatectomy or  
78 radiotherapy<sup>2</sup>, eventually 25% of patients will develop metastases for which there is currently  
79 no cure<sup>3-5</sup>. Treatment of choice for metastatic prostate cancer patients is androgen  
80 deprivation therapy (ADT) which reduces serum testosterone to castration levels, to which  
81 virtually all patients initially respond. However, metastatic disease progression despite  
82 ongoing ADT, termed metastatic castration-resistant prostate cancer (mCRPC), is  
83 inevitable<sup>6</sup>.

84

85 Androgen Receptor (AR) is a hormone-dependent transcription factor and the master  
86 regulator of prostate cancer development and progression. Upon androgen stimulation, AR  
87 alters its conformation, translocates into the nucleus<sup>7</sup> and associates to the chromatin at distal  
88 regulatory elements throughout the genome, hereafter referred to as its 'cistrome'. AR  
89 chromatin binding is facilitated by pioneer factors, such as FOXA1<sup>8</sup>, and operates under tight  
90 epigenetic control<sup>8,9</sup>. The majority of active AR sites are hallmarked by acetylation of lysine  
91 residue 27 on histone 3 (H3K27ac), a marker of active enhancers and promoters<sup>10,11</sup>. Upon  
92 formation of an active transcription complex, AR drives the expression of its target genes to  
93 control tumor cell growth. Following progression on ADT, further suppression of the AR  
94 signaling axis by new generation AR inhibitors, such as enzalutamide, is an effective  
95 treatment for mCRPC patients<sup>12,13</sup>.

96

97 Enzalutamide (ENZA) is a well-established therapy for the treatment of mCRPC. It  
98 significantly decreases the risk of radiographic progression and death among mCRPC  
99 patients in both the pre- and post-chemotherapy settings<sup>12,13</sup>. ENZA blocks AR signaling at  
100 multiple levels, including diminished AR chromatin binding, and prevention of coregulator  
101 recruitment<sup>14</sup>. However, intrinsic resistance to ENZA is observed in up to 46% of mCRPC  
102 patients and duration of response varies greatly between patients<sup>12,13</sup>. Consequently,  
103 biomarkers for response prediction to AR-targeted therapeutics, including ENZA, are urgently  
104 needed to identify those patients who may benefit from alternative treatment strategies.  
105 Moreover, combination treatments to overcome or postpone resistance to AR-targeted  
106 therapies, are urgently needed in the clinic.

107

108 Several studies have previously compared AR chromatin binding profiles in different disease  
109 stages and illustrated plasticity of AR cistromes in tumor development<sup>15,16</sup> and disease  
110 progression<sup>17,18</sup>, being predictive for outcome<sup>17</sup> and associated with treatment response in  
111 cell lines<sup>9</sup>. Despite our expanding knowledge of AR epigenetic alterations in prostate cancer  
112 patients and cell line models, there is limited knowledge on FOXA1 cistromics and H3K27ac  
113 profiles, in relation to drug resistance in mCRPC patients.

114

115 To identify the potential epigenetic alterations that drive ENZA response in mCRPC patients,  
116 metastasis-targeted biopsies were collected pre- and post- AR-targeting treatment, while  
117 response to treatment was monitored. Chromatin immunoprecipitation followed by massive  
118 parallel sequencing (ChIP-seq) was performed on all collected clinical specimens, charting  
119 the cistromes of H3K27ac, AR and FOXA1.

120

121 Comparative data analyses revealed a specific subset of 657 H3K27ac sites significantly  
122 enriched in metastatic lesions from mCRPC patients who did not respond to AR-targeted  
123 treatment. These sites were associated with response to castration in mCRPC PDX models,  
124 and regulate genes selectively expressed in ENZA-resistant cell line models, illustrating their  
125 potential to predict treatment response. Finally, we identified and functionally assessed  
126 factors that selectively bind to these 657 resistance-associated H3K27ac sites in cell line  
127 models, revealing novel therapeutic candidates and effective drug-drug combinations for  
128 treatment-resistant mCRPC patients.

129

## 130 **Methods**

### 131 *Study design and participants*

132 We conducted a single-arm, open-label, phase 2 study, in patients with mCRPC at the  
133 Netherlands Cancer Institute. Male patients over 18 years of age, with histologically  
134 confirmed adenocarcinoma of the prostate, Eastern Cooperative Oncology Group (ECOG)  
135 performance status 0-2, a serum testosterone level <50 ng/dl, scheduled for ENZA treatment  
136 and not previously treated with ENZA, with progressive disease, defined as a PSA rise  
137 (PCWG3 criteria<sup>19</sup>) and/or radiographic progression (RECIST 1.1 criteria<sup>20</sup>) and metastatic  
138 lesions of which a histological biopsy could safely be obtained, were included in the trial. This  
139 single center cohort study was conducted as a sub-investigation of the CPCT-02 biopsy  
140 protocol (NCT01855477), which aims to analyze the individual metastatic cancer genome in  
141 patients, to develop future personal predictors for response to systemic treatment. Trial  
142 procedures, treatment details, patient on-trial monitoring, definition of endpoints, sample size  
143 calculations and statistical analysis, are included in the supplementary trial data  
144 (Supplementary Data). This study was approved by the local medical ethics committee of the  
145 Netherlands Cancer Institute and was activated on January 24<sup>th</sup>, 2012. The protocol complied

146 with the ethical principles of the Declaration of Helsinki. Patients provided signed informed  
147 consent for translational studies and recording and analysis of baseline characteristics and  
148 clinical outcomes of ENZA treatment.

149

#### 150 *Tissue processing and chromatin immunoprecipitation analyses*

151 Biopsies were taken from a lymph-node metastasis or visceral metastasis selected by CT  
152 scan, while sites for a biopsy from a bone metastasis were selected by <sup>68</sup>Ga-PSMA PET  
153 scanning. Fresh-frozen metastatic biopsy samples from 64 CRPC patients was collected.  
154 The tumor percentage of these samples was scored on hematoxylin and eosin (H&E) stained  
155 slides by a dedicated pathologist. After tumor cell content was confirmed, chromatin  
156 immunoprecipitations were performed for AR, FOXA1 and H3K27ac at qualified samples as  
157 previously described<sup>21-23</sup>. In brief, lymph-node and visceral samples were cryo-sectioned into  
158 slices of 30μm, while bone samples were cryo-sectioned to slices of 10μm, and crosslinked  
159 using DSG (20593; Thermo Fisher Scientific) for 25 min. For each sample, 5μg of antibody  
160 and 50μl of either Protein A or Protein G magnetic beads (10008D or 10009D; Thermo Fisher  
161 Scientific) were used. Inputs for individual patients were generated as controls. Antibodies  
162 used were: AR (Millipore, 06-680), FOXA1 (Abcam, ab5089) and H3K27ac (Active motif,  
163 39133). Libraries were prepared and sequenced using the Illumina HiSeq2500 (65 bp, single  
164 end).

165

#### 166 *ChIP-seq data analysis*

167 Raw sequence data were aligned to hg19 using BWA v0.5.20. Aligned reads were filtered for  
168 mapping quality (MQ) > 20 using samtools v1.8<sup>24</sup>. Duplicate reads were marked using Picard  
169 MarkDupes function v2.18 (<http://broadinstitute.github.io/picard/>). Peaks were called using  
170 macs2 (v2.1.1)<sup>25</sup> with the fragment size determined using Phantompeakqualtools<sup>26</sup> against

171 corresponding input DNA for all samples. Phantompeakqualtools was used to identify the  
172 Relative Strand Cross-correlation (RSC)<sup>26</sup> and deepTools (v2.0)<sup>27</sup> to determine the fraction  
173 of reads in peaks (FRiP) and readcounts. Samples with RSC > 0.7, FRiP ≥ 1.0 and ≥ 8,000  
174 peaks were kept for further analysis (Supplementary Table 3). Snapshots of raw signal were  
175 generated using pyGenomeTracks (v3.6) with bigwig files<sup>28</sup>. Bigwig files were generated from  
176 aligned bam files using deepTools v2.0 bamCoverage function. To correlate read count data  
177 in 50kb bins across the genome for all samples and PDX samples, deepTools computeMatrix  
178 function was used on bigwigs followed by plotCorrelation. Visualization of raw reads was  
179 carried out with bigwigs using deepTools (v2.0) computeMatrix, plotHeatmap and plotProfile  
180 functions. For visualizing profiles of binding data between groups (non-  
181 responders/responders) at specific regions, aligned files from the samples within groups were  
182 merged and subsequently downsampled to equivalent readcounts (~20 million reads) using  
183 samtools and visualized using deepTools plotProfile. Principal component analysis was  
184 carried out using plotPCA function with the reads counted in peaks (dba.count function) from  
185 DiffBind package v2.4.8 in R v3.4.4. Supervised differential analyses using dba.analyze and  
186 resulting heatmap and volcano plot were generated using the DiffBind package (v2.4.8 in R  
187 v3.4.4) with the reads counted in peaks using the dba.count function using default DESeq2  
188 method. Volcano plot hexbin density tiles were plotted with R package hexbin (v1.28.1).  
189 Genomic features were assigned to differential peaksets using ChIPSeeker (v1.26.2)<sup>29</sup> in R  
190 (v4.0.3).

191  
192 To compare H3K27ac signal across various samples in our non-responder H3K27ac regions  
193 of interest, we first downloaded public PDX mCRPC H3K27ac ChIP-seq data<sup>18</sup> (GSE130408)  
194 and additional H3K27ac data from primary prostate cancer patient tumors (e.g. Gleason 7,9,  
195 cases, controls (GSE120738))<sup>30</sup> and aligned as above. In addition, we examined H3K27ac

196 data in the same manner from in-house generated datasets from treatment naïve metastatic  
197 samples, non-responder metastatic samples (this study), and publicly available healthy and  
198 primary tumor tissue (GSE130408)<sup>18</sup>. Visualizations of these data were generated with  
199 deepTools v2.0 computeMatrix followed by plotHeatmap of individual files and plotProfile as  
200 described above for binding data between groups.

201

202 For gene set enrichment, genes associated with H3K27ac non-responder sites (within 50kb  
203 of a transcription start site (TSS)) were identified in R (v4.0.3) using the ChIPSeeker package  
204 (v1.26.2)<sup>29</sup>. Enrichment tests for gene sets were performed in R (v4.1.2) using the  
205 GeneOverlap package (v1.30.0) and visualized in ggplot (v3.4.0). The average gene  
206 expression of these genes was calculated and plotted in public scRNA-seq from parental  
207 LNCaP cells and cells exposed to ENZA until resistance arose (RES-B<sup>31,32</sup>) using the Seurat  
208 package (v4.3.0)<sup>33</sup> in R (v4.1.2).

209

210 Readcounts and fraction of reads in peaks (FrlP) were visualized using the ggplot2 v2.3.3.0  
211 with Wilcoxon tests performed with ggpubr package v0.3.0 in R v3.5.0. To determine  
212 significant enrichment of our intervals with publicly available ChIP-seq data we queried our  
213 intervals against the CistromeDB transcription factor dataset<sup>34</sup> using the GIGGLE search  
214 function<sup>35</sup>. Prostate and prostate cancer experiments (Supplemental Table 5) were selected  
215 specifically for analysis. A scatterplot of the mean Enrichment score (combo\_score) for each  
216 factor was generated using ggplot v2.3.3.0 in R v3.5.0 (Supplemental Table 5).

217

### 218 *Patient-derived xenograft studies*

219 All animal experiments were performed after University of Washington IACUC approval  
220 following ARRIVE and NIH guidelines. Subcutaneous tumors were implanted in intact C.B.



221 17 SCID male mice (Charles River) and when tumors reached 100 mm<sup>3</sup> animals were  
222 randomized to control and castrated groups. Tumor growth and body weights were monitored  
223 twice a week. Animals were sacrificed at the end of the study or when animals became  
224 compromised. Responses to castration were also fully described previously<sup>36</sup>. The doubling  
225 time was estimated using exponential (Malthusian) growth model. If only one value was  
226 available, doubling time was not computed. For samples with a negative doubling time, the  
227 value was re-normalized to the mean value of the corresponding control model yielding a  
228 positive value. Significant differences between classes determined by one-way ANOVA  
229 followed by post-hoc Tukey HSD test. Visualization was carried out in R using ggplot (v3.3.6)  
230

#### 231 *Cell lines and culture conditions*

232 Castration-resistant prostate cancer models (LNCaP-Abl and LNCaP-16D<sup>37</sup>) were kindly  
233 provided by Helmut Klocker<sup>38</sup> and Amina Zoubeidi<sup>39</sup>. ENZA resistant LNCaP derivatives  
234 LNCaP-Enz<sup>R</sup> were kindly provided by the Donald Vander Griend<sup>40</sup>. LNCaP-Abl cells were  
235 cultured in RPMI-1640 medium containing 10% DCC (hormone deprived FBS), LNCaP-16D<sup>37</sup>  
236 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, and LNCaP-Enz<sup>R</sup>  
237 cells were cultured in RPMI-1640 medium containing 10% FBS and 10 $\mu$ M ENZA. All cell lines  
238 were authenticated and tested for mycoplasma contamination.

239

#### 240 *siRNA screen proliferation assay and analyses*

241 siRNAs were purchased from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA and  
242 siPLK1 were applied as positive and negative controls. 5 $\mu$ l of 50nM siRNA pools were seeded  
243 in individual wells of a 96 well-plate. Cells were reverse transfected with 5 $\mu$ l 1% Lipofectamine  
244 RNAiMAX Reagent (Invitrogen, Eindhoven, Netherlands) in Optimem (Thermofisher,  
245 Eindhoven, Netherlands) in 90 $\mu$ l culture medium. For LNCaP-Abl and LNCaP-16D, 10.000

246 cells were seeded per well, and 20.000 cells for LNCaP-Enz<sup>R</sup> cells. Optimal experimental  
247 setup was determined for each cell line and after 7 (LNCaP-16D), 9 (LNCaP-Abl) and 10  
248 (LNCaP-Enz<sup>R</sup>) days, cell viability was determined using CellTiter-Blue and values were  
249 normalized over siControl. After incubating for 3 hours, viability was measured using a  
250 fluorescence reader (EnVision 2014).

251

252 The primary pooled siRNA and validation deconvolution screen were analysed in the  
253 following way. Using the CellTiter-Blue measurements of the positive and negative controls,  
254 a z'factor was calculated per plate and plates with a z'factor < 0 were removed from the  
255 dataset. The data was then normalized using Normalized percent inhibition<sup>41</sup>. After  
256 normalization, correlations between replicate plates were calculated and plates which did not  
257 correlate well with the other replicate plates, were removed. Over the replicates a mean value  
258 was calculated. Per condition a normalized distribution for mean values of the negative  
259 controls was approximated based on mean and SD value, and used to calculate for each  
260 pooled siRNA a p-value, which was corrected for multiple testing using the Benjamini-  
261 Hochberg method. From the primary screen an initial selection was made of the siRNA pools  
262 that were a hit in at least two out of three cell lines, which produced a list of 11 hits. The 11  
263 hits from the primary pooled screen were subsequently selected for a  
264 deconvolution validation screen, in which four individual siRNAs were tested separately. All  
265 targets with two individual siRNAs with among replicates a mean  $\leq 0.7$  and FDR  $\leq 0.1$ , where  
266 considered validated hits. All calculation were done in R.

267

268 Expression levels per target gene in siRNA deconvolution experiments were assessed by  
269 means of qPCR analysis, using specific primer-pairs for ACTB (5'-  
270 CCTGGCACCCAGCACAAT-3', 5'-GGGCCGGACTCGTCATACT-3'), FOXA1 (FW 5'-

271 GTGAAGATGGAAGGGGCATGAA-3', REV 5'-CCTGAGTTCATGTTGCTGACC-3'), ASH2L  
272 (FW 5'-CTGACGTCTTGTATCACGTG-3', REV 5'-GCATCTTTGGGAGAACATTTG-3'),  
273 GATA2 (FW 5'-GACAAGGACGGCGTCAAGTA-3', REV 5'-GGTGCCCATAGTAGCTAGGC-  
274 3') and HDAC3 (FW 5'-ACGGTGTCTTCCACAAATACG-3', REV 5'-  
275 GGTGCTTGTA ACTCTGGTCATC-3'). In brief, after siRNA transfection using the  
276 abovementioned protocol RNA was isolated using RNAGEM kit (MicroGEM), and quantified  
277 by Quant-iT™ RiboGreen™ RNA Assay Kit (Thermo Fisher Scientific), following  
278 quantification cDNA was synthesized using the SuperScript™ III Reverse Transcriptase  
279 system (Thermo Fisher Scientific, USA) with random hexamer primers according to the  
280 instructions provided by manufacturers. Quantitative PCR (qPCR) was performed using the  
281 SensiMix™ SYBR Kit (Bioline, UK) according to the manufacturer's instructions on a  
282 QuantStudio™ 6 Flex System (Thermo Fisher Scientific, USA). All data was firstly normalized  
283 over ACTB expression, and then over the siControl values. For all primer pairs, 2 biological  
284 replicates with 2 technical replicates each were analyzed.

285

#### 286 *PDX in vitro studies*

287 Subcutaneous tumors were harvested and dissociated using the Miltenyi gentleMACS  
288 system with a Human Tumor dissociation kit (Miltenyi Corp). Cells were seeded in clear  
289 bottom white -walled flat bottom 96-well plates (20,000 cells per well) in RPMI and 10% FBS.  
290 ENZA (MedChem Express) and vorinostat (MedChem Express) 10mM in DMSO and diluted  
291 with RPMI to indicated concentrations. Effects of the treatments were evaluated after 5  
292 days using CellTiter-Glo (Promega).

293

#### 294 *Drug synergy assessment*

295 In a 384-well plate, 500 LNCaP or LNCaP-16D cells were seeded and treated with various  
296 concentrations of ENZA (MedChemExpress, Monmouth Junction NJ, USA) and vorinostat  
297 (kindly provided by Rene Bernards, NKI). Five days later, the CellTiter Glo assay (Promega  
298 Benelux BV, Leiden, Netherlands) was performed according to the manufacturer's  
299 instruction. All the assays were performed in biological quadruplicates (n=4). All the  
300 conditions (single and combination) were normalized to non-treated condition (set at 100).  
301 SynergyFinder 2.0<sup>42</sup> was used to evaluate and plot synergistic potential using highest-single  
302 agent (HSA) synergy reference model. Response of the two cell lines to single agent  
303 vorinostat was also investigated and plotted using the normalized viability in full media (FBS)  
304 and area under the curve (AUC) method.

305

#### 306 *Single-cell analyses*

307 Single-cell RNA-seq (GSE168669) data was used to produce UMAP visualizations of LNCaP  
308 parental and LNCaP RES-B retaining cluster identities from Taavitsainen *et al.*<sup>32</sup> The genes  
309 proximal to the 657 non-responder H3K27ac sites were compiled into a gene set expression  
310 analysis to produce scores per cell with AddModuleScore function from Seurat (version  
311 4.3.0). Previously identified single-cell clusters (clusters 0 to 12)<sup>32</sup> were used in the  
312 enrichment analysis to overlap genes proximal to the 657 non-responder H3K27ac sites.

313

## 314 **Results**

### 315 **Phase II trial of AR-targeted therapy in patients with mCRPC**

316 To identify novel epigenetic biomarkers, we conducted a single-arm, open-label, phase 2  
317 study in patients with mCRPC treated with a new line of AR targeted therapy, being a sub-  
318 investigation of the CPCT-02 biopsy protocol (NCT01855477) (Figure 1A). Between  
319 September 2014 and April 2019, a total of 64 mCRPC patients were enrolled in the trial.

320 Baseline characteristics are summarized in Supplementary Table 1, trial outcomes in  
321 Supplementary Table 2 and Supplementary Figure 1: Consort diagram, with in-depth  
322 description of relevant clinicopathological parameters and outcomes included in the  
323 supplementary clinical trial data section (Supplementary Data).

324

### 325 **Biopsy assessment and evaluable population for biomarker discovery**

326 All 64 patients had a pre-treatment biopsy from a metastatic lesion. Biopsy sites from the  
327 whole population include bone (n=19; 29.7%), lymph-nodes (n=32; 50.0%) and visceral  
328 organs (n=13; 20.3%) (Supplementary Table 1). A second biopsy (post-treatment) was taken  
329 upon disease progression for 15 patients. Biopsies with  $\geq 30\%$  tumor cells were further  
330 processed for downstream molecular analyses (42 and 12 for pre- and post-treatment,  
331 respectively) (Supplementary Figure 1: Consort diagram). We successfully generated ChIP-  
332 seq data for active promoter/enhancer histone modification H3K27ac —passing stringent QC  
333 requirements (See Methods) for 22 out of the 42 samples. Four (18.2%) of the pre-treatment  
334 biopsies evaluable for biomarkers, were from bone metastases, while 13 (59.1%) were from  
335 lymph-node metastases and 5 (22.7%) from visceral metastases (Supplementary Table 1).  
336 For 6 of 15 post-treatment biopsies, we obtained high quality H3K27ac ChIP-seq data. One  
337 (16.7%) of the post-treatment biopsies was from bone, 3 (50.0%) were from lymph-nodes  
338 and 2 (33.3%) were from visceral organs. One patient had both pre- and post-treatment  
339 biopsies resulting in 28 biopsy samples for further analyses from 27 unique patients. The  
340 baseline characteristics and treatment outcomes of the 22 patients who donated an evaluable  
341 pre-treatment biopsy and the 6 patients who donated an evaluable post-treatment biopsy,  
342 are summarized in Supplementary Table 1 and Supplementary Table 2, respectively. There  
343 were no significant differences in baseline age, serum PSA, the treatment outcomes, duration  
344 of treatment, PSA change from baseline, and Time to PSA Progression (TTPP) between the

345 patients who donated an evaluable pre- and/or post-treatment biopsy and the whole  
346 population (Supplementary Table 1 and Supplementary Table 2). Additional clinical  
347 information and methods can be found in Supplementary Information.

348

349 Prior to functional genomic downstream analyses, all patients were categorized for their  
350 overall response, which was a composite of three outcomes: (1)  $\geq 50\%$  PSA decrease from  
351 baseline, (2) radiographic response (stable disease, partial response or complete response),  
352 and (3) longer than median TTPP. Assessment was conservative; in case a patient could not  
353 be evaluated on a particular outcome measure, it was considered as no response. All patients  
354 were evaluable for this endpoint, except for one patient (1.6%) who could not be evaluated  
355 for any of the three outcomes (Supplementary Table 2). In the whole population, 23.4% of  
356 patients scored on all three items (Response to ENZA), 37.5% of patients did not score on  
357 any item (No response to ENZA) and the remaining 37.5% of patients had inconsistent  
358 responses on the three outcome measures listed above (Intermediate response to ENZA).  
359 Of the 22 patients in the pre-treatment evaluable population, 6 (27.3%) patients had a  
360 response, 8 (36.4%) patients had an intermediate response, and 8 (36.4%) patients had no  
361 response to ENZA (Supplementary Table S2). Of the 6 patients in the post-treatment  
362 evaluable population, 2 patients had a response (33.3%), 2 patients had an intermediate  
363 response (33.3%), 1 patient had no response (16.7%) to ENZA treatment, while 1 patient  
364 was not evaluable (16.7%) (Supplementary Table S2). Based on the ChIP-seq QC  
365 parameters and clinical assessment of our trial data, 28 biopsies (22 pre- and 6 post-  
366 treatment, from 27 unique patients) with high quality ChIP-seq data are available, roughly  
367 equally sized response groups were formed, with 8 responders, 10 intermediate and 9 non-  
368 responders to treatment (one unknown) (Figure 1B).

369

## 370 **Genome-wide epigenetic profiling of mCRPC**

371 Apart from H3K27ac ChIP-seq data, for which we successfully generated high-quality data  
372 for 28 metastatic biopsy samples (see above), 10 FOXA1 ChIP-seq and 2 AR ChIP-seq  
373 datasets were generated on these fine needle core biopsies (Figure 1B and Supplementary  
374 Figure 1: CONSORT diagram). As all these patients received prior ADT, the low circulating  
375 testosterone levels may explain the relatively low success-rate of AR ChIP-seq (of which  
376 chromatin binding is decreased following ADT) as compared to FOXA1. For peak numbers,  
377 read counts and other relevant ChIP-seq QC parameters, see Supplementary Table 3 and  
378 Supplementary Figure 2A,B.

379  
380 All H3K27ac ChIP-seq samples were highly correlated based on genome-wide patterns  
381 (Figure 1B) indicating low inter-tumor heterogeneity, and robust technical reproducibility. As  
382 expected, and in line with our previous study on multiple metastases from the same patient<sup>22</sup>,  
383 FOXA1 and AR profiles were intermingled in our unsupervised hierarchical analysis reflecting  
384 the direct biological interplay between these two factors<sup>16,43</sup>. No correlation was observed  
385 with metastatic site or treatment condition/status or clinical response in the clustering with all  
386 factors (Figure 1B), nor on H3K27ac alone (Supplementary Figure 3A,B). As H3K27ac ChIP-  
387 seq data represented the largest and most-complete dataset, we decided to first focus on  
388 these samples. For H3K27ac profiles, we found comparably high-quality peaks across all  
389 three response groups, as exemplified on single locus (Figure 1C) and genome-wide scale  
390 (Figure 1D). Taken together, our data indicate the vast majority of H3K27ac sites are  
391 overlapping across sample types, irrespectively of AR-targeted therapy response.

392

## 393 **Distinct H3K27ac profiles identify mCRPC tumors resistant to AR-targeted therapy**

394 While the total universe of H3K27ac profiles did not differ between response groups of  
395 patients, possible subsets of regions may still exist that stratify patients on outcome. To  
396 ensure that subtle differences in cut-offs and definitions of treatment response would not  
397 affect data interpretation, we performed supervised differential binding analysis<sup>44</sup> with the  
398 H3K27ac data in the most extreme treatment response groups (responder and non-  
399 responder) (Figure 2A). In total, we observed 682 H3K27ac regions that significantly differed  
400 between these response groups, with 657 sites selectively enriched in non-responder  
401 patients and merely 25 sites found selectively enriched in responders ( $\text{adj.p} \leq 0.05$ ,  $\text{logFC} \geq$   
402  $\text{abs}|2|$ , Figure 2B). As expected for H3K27ac ChIP-seq, both sets of sites are predominantly  
403 found in distal intergenic regions (Supplementary Table 4). Differentially enriched peaks  
404 between responders and non-responders were robust, as exemplified for three genomic loci  
405 (Figure 2C), and quantified showing enriched signal in non-responders compared to  
406 responders across all non-responder sites (Figure 2D).

407

408 To determine whether the 657 H3K27ac sites enriched in non-responders represent an  
409 acquired feature of mCRPC, or whether H3K27ac signal at these regions is already present  
410 in the primary disease setting and associated with aggressiveness, we re-analyzed H3K27ac  
411 ChIP-seq data from a matched case-control cohort of treatment naïve primary prostate  
412 cancer patients that we reported previously<sup>30</sup>. We observed no difference in H3K27ac signal  
413 at these sites based on case/control status (Supplementary Figure 4A), nor on Gleason score  
414 (7 versus 9) (Supplementary Figure 4B) while typical signal for known primary-specific AR  
415 binding sites was clearly present<sup>16</sup> (Supplementary Figure 4C). Further supporting the notion  
416 that these regions are acquired in the treatment-resistance metastatic setting, we observed  
417 stronger signal in the non-responder metastatic samples (this study) compared with treatment  
418 naïve metastasis samples and previously reported primary prostate cancer samples<sup>18</sup> as well



419 as healthy prostate tissue<sup>18</sup> (Supplementary Figure 4D). Together, these data suggest that  
420 the resistance-associated H3K27ac sites represent an mCRPC-unique feature of resistance  
421 to AR-targeted therapy. Collectively, our data indicate that a specific subset of H3K27ac sites  
422 enables us to stratify mCRPC patients for an outcome to third generation AR inhibitor  
423 treatment.

424

### 425 **Resistance-associated H3K27ac profiles predict response to castration in mCRPC** 426 **patient-derived xenografts**

427 H3K27ac profiling in clinical samples allowed us to stratify tumors from mCRPC patients on  
428 response to AR-targeted therapeutics. To independently validate these findings and to  
429 explore the potential for stratification beyond our own study, we next investigated an existing  
430 H3K27ac ChIP-seq dataset that we previously reported for mCRPC PDX samples<sup>18</sup>. The  
431 PDX models were generated from CRPC prostate cancer tumors, and represent metastatic  
432 samples from multiple metastatic sites, including adrenal glands, ascites, bladder, bone,  
433 bowel, lymph-node and liver<sup>36</sup>. Originally, to determine the hormone-dependency of the PDX  
434 tumor growth, PDX tumors were grown in testosterone proficient male mice, after which the  
435 animals were either castrated or left intact (see overview in Figure 3A).

436

437 To evaluate whether the PDX tumors would classify according to the 657 non-responder  
438 H3K27ac sites, we plotted H3K27ac ChIP-seq data for these sites in 15 available PDX  
439 samples (Figure 3B and Figure 3C). Interestingly, 7 PDXs (45%) displayed strong H3K27ac  
440 signal at these regions, while the remaining 8 PDX samples (55%) displayed weak signal at  
441 these sites; with no significant global differences between these two groups of samples  
442 (Supplementary Figure 5). Integrating these cistromic data with the *in vivo* response-to-  
443 castration data showed that a strong H3K27ac signal is correlated with less tumor regression

444 upon castration of the animals (Figure 3D, raw data Supplementary Figure 6). In contrast,  
445 PDXs with weak H3K27ac signal at our clinically observed H3K27ac non-responder sites,  
446 showed tumor regression upon animal castration. Importantly, using single-cell RNA-seq data  
447 (scRNA-seq) from prostate cancer cell lines, we find genes associated with our clinically  
448 observed H3K27ac non-responder sites as significantly enriched in a cell cluster that  
449 selectively appears in LNCaP-derived ENZA-resistant cells<sup>32</sup> (cluster 3) (Figure 3E). After  
450 long-term treatment with ENZA, cluster 3 enriched mainly for LNCaP RES-B resistant cells  
451 and only partially for RES-A cells. In fact, in LNCaP RES-B cells cluster 3 was expanded  
452 compared to parental cells and also compared to RES-A, indicating that these cells drive  
453 resistance-specific biology. In addition, average gene expression of genes associated with  
454 H3K27ac non-responder sites was linked with cluster 3 expansion (Figure 3F). Interestingly,  
455 scATAC-seq (single cell Assay for Transposase-Accessible Chromatin using sequencing)  
456 clusters identified previously to be associated with scRNA-seq cluster 3<sup>32</sup>, indicated no  
457 selective enrichment of known transcription factors involved in treatment-mediated chromatin  
458 reprogramming in prostate cancer. Together, these data illustrate that distinct H3K27ac  
459 signals stratifying patients for response to AR blockade, and we validated the same profiles  
460 in mCRPC PDX models and at the single-cell level in models of ENZA resistance.

#### 461 462 **Driver identification for resistance to AR inhibition in mCRPC**

463 Using the combined datastreams of H3K27ac ChIP-seq and response-to-castration in PDX  
464 models, we successfully validated our 657 H3K27ac sites as indicative for unresponsiveness  
465 to hormonal intervention in mCRPC. As no selective transcription factor usage was enriched  
466 upon integrating scRNA-seq and scATAC-seq data, we conclude that possibly multiple  
467 factors -or proteins binding the genome without direct DNA recognition motif, drive resistance.  
468 Therefore, instead of TF motif analyses, we used GIGGLE; a genomics search engine that

469 queries previously-reported protein/chromatin occupancy datasets and ranks the significance  
470 of genomic loci shared between query and a database of regions<sup>35</sup>. Specifically, we analyzed  
471 an extensive database of ChIP-seq experiments from prostate tissue-derived cell lines and  
472 prostate cancer cell lines<sup>34,45</sup> (Supplementary Table 5) to explore which DNA-associated  
473 proteins bind at our defined non-responder H3K27ac sites (Figure 4A). This analysis  
474 identified multiple factors previously reported to drive resistance to ENZA treatment or  
475 castration, including HNF4G<sup>46</sup>, NR3C1 (glucocorticoid receptor)<sup>47-49</sup> and FOXA1<sup>50</sup>  
476 (Supplementary Table 5). To clinically validate the cell line-based GIGGLE enrichment data,  
477 we next analyzed the FOXA1 ChIP-seq data from our mCRPC samples, separating the non-  
478 responder (n=4) and responder (n=3) samples. These analyses revealed selective  
479 enrichment of FOXA1 binding at the 657 non-responder H3K27ac sites in mCRPC samples  
480 from non-responder patients, confirming the GIGGLE enrichment data (Figure 4B).

481

482 Next, we sought to explore the functional involvement of top-enriched factors (Supplementary  
483 Table 5) in driving resistance to AR blockade (essential genes in our setting), by designing  
484 and performing a focused siRNA screen (4 pooled siRNAs per target (genes with median  
485 GIGGLE combo enrichment score >20)) to target genes in two cell line models of castration  
486 resistance (LNCaP-Abl<sup>38</sup> and LNCaP-16D<sup>37</sup>) as well as a model of ENZA resistance (LNCaP-  
487 Enz<sup>R</sup>)<sup>40</sup> (Figure 4C). From the pooled siRNA experiments, eleven hits that significantly  
488 diminished proliferation in at least two out of three cell lines (Figure 4D), relative to siControl  
489 and were identified as top-enriched factors in the GIGGLE analysis, were selected for  
490 deconvolution experiments in castration-resistant LNCaP-16D. Single siRNAs were tested  
491 individually, in which decreased cell proliferation potential observed for at least 2 out of 4  
492 siRNAs was considered a validated hit. These analyses identified factors previously  
493 described as critical in driving resistance to both ENZA and castration in prostate cancer cell

494 lines: FOXA1<sup>50</sup> and GATA2<sup>51</sup> (Figure 4E, Supplementary Figure 7). Furthermore, two factors  
495 previously reported to be associated with castration resistance, but not studied before for  
496 their potential involvement in driving resistance to ENZA, were identified: HDAC3<sup>52</sup> and  
497 ASH2L<sup>53</sup>. Collectively, these studies revealed potential drivers and possible drug targets to  
498 treat castration-resistant prostate cancer.

499

## 500 **Histone deacetylase (HDAC) inhibition synergizes with enzalutamide to block mCRPC** 501 **cell growth**

502 Computational analyses and perturbation studies identified five factors of potential  
503 therapeutic interest. As transcription factors are considered challenging drug targets, we  
504 focused on HDAC3 for further downstream studies. HDAC3 has previously been reported as  
505 therapeutic target in castration-resistant prostate cancer<sup>52</sup>, but remains unexplored in the  
506 ENZA-resistant setting. Highly selective HDAC3 inhibitors have been described but have not  
507 been explored for efficacy and tolerability in clinical trials<sup>54</sup>. Less specific HDAC inhibitors are  
508 well characterized and clinically implicated in the treatment of several cancer types, including  
509 vorinostat in the treatment of cutaneous T-cell lymphoma<sup>55</sup>. Vorinostat has been previously  
510 reported to block proliferation of prostate cancer cells<sup>56</sup> and to synergize with the AR-  
511 antagonist bicalutamide<sup>57</sup>. Consequently, HDAC inhibitors have the potential to overcome  
512 resistance to established mCRPC treatments, including AR targeted drugs<sup>58</sup>. A significant  
513 increase in sensitivity to HDAC inhibition was observed in castration-resistant LNCaP-16D  
514 cells relative to hormone-sensitive parental LNCaP cells (Supplementary Figure 8.  
515 Importantly, in both LNCaP cells and LNCaP-16D cells, vorinostat synergized with ENZA  
516 (Figure 4F, Supplementary Figure 9A). To further establish therapeutic proof-of-concept,  
517 subcutaneous PDX tumors were dissociated and treated *ex vivo* with increasing  
518 concentrations of ENZA, vorinostat, or both, which allowed us to determine synergy (Figure

519 4G). In agreement with the cell line-based results, *ex vivo* drug response in mCRPC PDXs  
520 confirmed synergistic interactions between vorinostat and ENZA (Figure 4G, Supplementary  
521 Figure 9A, 9B).

522

523 In summary, by performing H3K27ac ChIP-seq analyses of metastatic lesions from mCRPC  
524 patients, we identified an epigenetics-based classification for response prediction to AR-  
525 targeted therapy which we successfully validated in mCRPC PDX mouse models. These  
526 analyses revealed drivers for resistance to AR-targeted therapeutics, and identified ENZA in  
527 combination with pan-HDAC inhibitor vorinostat as a novel synergistic and highly effective  
528 drug combination for the treatment of castration-resistant prostate cancer.

529

## 530 **Discussion**

531 The clinical significance of the non-protein coding genome in prostate cancer is rapidly  
532 gaining attention. Recently, whole-genome sequencing of primary prostate cancer  
533 specimens revealed enrichment of somatic mutations in AR chromatin binding sites<sup>59,60</sup>, a  
534 subset of which functionally affected enhancer activity<sup>15</sup>. Not only in primary prostate cancer  
535 but also in the mCRPC setting, non-coding somatic alterations have been reported, including  
536 amplification of enhancer elements that regulate expression of AR<sup>61,62</sup>, HOXB13<sup>18</sup> and  
537 FOXA1<sup>18</sup>. In addition to somatic alterations in the primary DNA sequence or copy number,  
538 modifications in epigenetic regulatory elements are proving crucial in prostate cancer  
539 development and progression. Furthermore, extensive epigenetic reprogramming and AR  
540 enhancer plasticity have been related to tumorigenesis<sup>15,16</sup> and progression<sup>18</sup>, as well as  
541 therapy resistance<sup>17</sup>. To date, deviations in enhancer regulation have not been extensively  
542 studied in castration-resistant disease and have not been explored in the context of a  
543 controlled clinical trial. Here, we interrogated the epigenome in relation to AR-targeted

544 therapy response in mCRPC patients. Within our clinical cohort, epigenetic features revealed  
545 a robust classification scheme predicting response to treatment. These findings additionally  
546 revealed potential drivers of resistance as well as novel therapeutic drug combinations to  
547 combat castration-resistant disease.

548

549 While ENZA improves outcome in patients with mCRPC<sup>12,13</sup>, a significant proportion of  
550 mCRPC patients experience no response to AR-targeting treatment due to intrinsic  
551 resistance mechanisms. Supporting the notion of a pre-existing treatment resistance patient  
552 population, we found that H3K27ac profiles in mCRPC tumors remained unaltered following  
553 ENZA treatment. These data suggest that these cancers were already resistant prior to drug  
554 exposure, harboring epigenetic programs that support AR-independent cellular growth. In  
555 contrast, most previously described resistance mechanisms appeared to be treatment-  
556 induced, including AR mutations<sup>63-65</sup> and amplification<sup>40</sup>, GR upregulation<sup>47-49</sup> or enrichment  
557 of HNF4G<sup>46</sup>. As the tumor samples we analyzed were already relapsed after prior therapies  
558 and developed castration resistance, it is plausible that the induction of the abovementioned  
559 resistance mechanisms occurred before our samples were taken. At the single-cell level,  
560 genes associated with our H3K27ac non-responder sites were significantly enriched in an  
561 ENZA-resistance-associated cluster which expands after long-term treatment<sup>32</sup>, indicating  
562 that the acetylated regions we have identified – and associated genes – are important in  
563 driving therapeutic resistance in a subset of tumors. These results may jointly point towards  
564 the induction of divergent castration resistance mechanisms, which either sustain hormone-  
565 dependency (as in the case for our ‘responder’ population) or diverge towards complete  
566 hormone-independence (our ‘non-responder’ population), in which other transcription factors  
567 compensate for the lack of AR activity.

568 Apart from the hormone receptor family, transcription factors are generally considered  
569 challenging drug targets and potential other therapeutic strategies – such as epigenetic drugs  
570 – may prove of clinical benefit for these cases. Along these lines, for three of our hits: NKX3-  
571 1, FOXA1 and GATA2, specific inhibitors are yet to be developed. Recently, indirect small  
572 molecule inhibition of FOXA1 has been described, by means of targeting EZH2<sup>66</sup> and LSD1<sup>67</sup>,  
573 presenting a potential direct therapeutic avenue in this setting.

574 As HDAC3 expression has been shown to be critical for AR-driven transcriptional programs  
575 – both in hormone-sensitive and castration-resistant cell line models<sup>68</sup> – we chose to further  
576 study the potential benefit of HDAC inhibition as a therapeutic strategy in mCRPC. Our data  
577 reveal that HDAC3 is also critically involved in resistance to AR-targeted therapeutics in the  
578 mCRPC setting, and prove therapeutic proof-of-concept of a synergistic drug-drug interaction  
579 between ENZA and the pan-HDAC inhibitor vorinostat, both in cell line models and mCRPC  
580 PDX-derived explants. This drug has been clinically approved in the treatment of cutaneous  
581 T cell lymphomas and also shown promise as a therapeutic strategy in advanced non-small  
582 cell lung cancer<sup>69</sup>. Although, vorinostat showed no activity as a single agent in mCRPC  
583 patients, a phase 2 trial into the combination of the non-selective HDAC inhibitor panobinostat  
584 and the AR targeted drug bicalutamide in 55 patients, showed promising results<sup>70,71</sup>.  
585 Common drug-related serious adverse events such as thromboembolic events associated  
586 with vorinostat are of concern<sup>55</sup>, but may be avoided with the likely lower concentrations used  
587 in a combination with ENZA.

588

589 **Conclusions**

590 Based on our results, new clinical trials for testing vorinostat – or other HDAC inhibitors – in  
591 conjunction with ENZA for mCRPC patients would be justified, since novel highly-effective  
592 drug-drug combinations are urgently needed to combat this deadly disease.

593

594

## 595 **Declarations**

### 596 *Ethical Approval and Consent to Participate*

597 The trial was approved by the institutional review board of the Netherlands Cancer Institute,  
598 written informed consent was signed by all participants enrolled in the study, and all research  
599 was carried out in accordance with relevant guidelines and (inter-)national and ethical  
600 standards. Within the General Data Protection Regulation, patients always had the  
601 opportunity to object or actively consent to the (continued) use of their personal data and  
602 biospecimens for research purposes.

603

### 604 *Consent for Publication*

605 All authors have read the manuscript and consent to publication.

606

### 607 *Availability of Supporting Data*

608 Raw ChIP-sequence data are deposited in the European Genome-Phenome Archive  
609 (EGAS00001006161)

610

### 611 *Competing Interests*

612 WZ and AMB received research funding from Astellas Pharma for the work performed in this  
613 manuscript. All other authors declare no competing interests.

614

### 615 *Funding*

616 This work is supported by Astellas Pharma Europe BV (WZ, AMB), The Prostate Cancer  
617 Foundation (Challenge Award – MLF, MMP, WZ, TMS); The United States Department of  
618 Defense (Idea Award, PC180367 – MLF, MMP, WZ); OncoCode Institute (WZ), KWF Dutch  
619 Cancer Society / Alpe d’HuZes (10084 – WZ, AMB and 7080 – AMB, MSvdH, LW), PNW  
620 Prostate Cancer SPORE (P50CA097186, P01CA163227 – EC) and Craig Watjen Memorial  
621 funds (EC); Academy of Finland (#349314 – AU) and Norwegian Cancer Society (#198016-  
622 2018 – AU); S. H. and M.N. Academy of Finland (#312043, #310829).

623



624 *Authors' Contributions*

625 TMS, YZ, SP, WZ and AMB wrote the main manuscript text. TMS, YZ, SP, KS, HMN, LGB,  
626 SH, YK, JK, SL, SS, CL, VvdN, JS, BM, GJ, GFJLvL, AU, RLB, EC, WZ and AMB prepared  
627 and analyzed data for all figures and tables. All other authors reviewed the manuscript.  
628

629 *Acknowledgments*

630 The authors gratefully acknowledge the patients and the families of patients who contributed  
631 to this study. We thank the NKI Genomics Core Facility, Core Facility Molecular Pathology  
632 and Biobanking, Research High Performance Computing Facility, Scientific Information  
633 Service for their excellent technical support and all group members from the Zwart, Bergman  
634 and Corey labs for highly constructive feedback and suggestions. The authors thank the A.U.  
635 Norwegian Cancer Society, Academy of Finland and Cancer Foundation Finland, S.H. and  
636 M.N. Academy of Finland and Sigrid Jusélius Foundation, Finnish Cancer Institute.  
637

638 *Authors' Information*

639 \*Tesa M. Severson: Divisions of Oncogenomics and Molecular Carcinogenesis, The  
640 Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the  
641 Netherlands

642  
643 \*Yanyun Zhu: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the  
644 Netherlands, Oncode Institute, Utrecht, the Netherlands

645  
646 \*Stefan Prekovic: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,  
647 the Netherlands, Oncode Institute, Utrecht, the Netherlands

648  
649 Karianne Schuurman: Division of Oncogenomics, The Netherlands Cancer Institute,  
650 Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands

651  
652 Holly M. Nguyen: Department of Urology, University of Washington, Seattle, WA, USA

653  
654 Lisha G. Brown: Department of Urology, University of Washington, Seattle, WA, USA

655  
656 Sini Hakkola: Prostate Cancer Research Center, Faculty of Medicine and Health Technology,  
657 Tampere University and Tays Cancer Centre, Tampere, Finland

658  
659 Yongsoo Kim: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the  
660 Netherlands. Present working address: Department of Pathology, Cancer Center  
661 Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

662  
663 Jeroen Kneppers: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,  
664 the Netherlands, Oncode Institute, Utrecht, the Netherlands

665  
666 Simon Linder: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the  
667 Netherlands, Oncode Institute, Utrecht, the Netherlands

668

- 669 Suzan Stelloo: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the  
670 Netherlands. Present working address: Department of Molecular Biology, Faculty of Science,  
671 Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University,  
672 Nijmegen, 6525 GA Nijmegen, the Netherlands.  
673
- 674 Cor Liefink: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,  
675 Amsterdam, the Netherlands  
676
- 677 Michiel van der Heijden: Division of Molecular Carcinogenesis, The Netherlands Cancer  
678 Institute, Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands  
679 Cancer Institute, Amsterdam, the Netherlands  
680
- 681 Matti Nykter: Prostate Cancer Research Center, Faculty of Medicine and Health Technology,  
682 Tampere University and Tays Cancer Centre, Tampere, Finland  
683
- 684 Vincent van der Noort: Department of Biometrics, The Netherlands Cancer Institute,  
685 Amsterdam, the Netherlands  
686
- 687 Joyce Sanders: Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the  
688 Netherlands  
689
- 690 Ben Morris: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,  
691 Amsterdam, the Netherlands  
692
- 693 Guido Jenster: Department of Urology, Erasmus MC, Rotterdam, the Netherlands  
694
- 695 Geert JLH van Leenders: Department of Pathology, Erasmus MC Cancer Institute, University  
696 Medical Centre, Rotterdam, the Netherlands  
697
- 698 Mark Pomerantz: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard  
699 Medical School, Boston, MA, USA  
700
- 701 Matthew L. Freedman: Department of Medical Oncology, Dana-Farber Cancer Institute,  
702 Harvard Medical School, Boston, MA, USA, The Eli and Edythe L. Broad Institute,  
703 Cambridge, MA, USA  
704
- 705 Roderick L. Beijersbergen: Division of Molecular Carcinogenesis, The Netherlands Cancer  
706 Institute, Amsterdam, the Netherlands  
707
- 708 Alfonso Urbanucci: Prostate Cancer Research Center, Faculty of Medicine and Health  
709 Technology, Tampere University and Tays Cancer Centre, Tampere, Finland, Department of  
710 Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway  
711
- 712 Lodewyk Wessels: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,  
713 Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands, Department of  
714 EEMCS, Delft University of Technology, Delft, The Netherlands  
715
- 716 Eva Corey: Department of Urology, University of Washington, Seattle, WA, USA  
717

718 #Wilbert Zwart: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,  
719 the Netherlands, Oncode Institute, Utrecht, the Netherlands, Laboratory of Chemical Biology  
720 and Institute for Complex Molecular Systems, Department of Biomedical Engineering,  
721 Eindhoven University of Technology, Eindhoven, the Netherlands

722  
723 #Andries M. Bergman: Division of Oncogenomics, The Netherlands Cancer Institute,  
724 Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands Cancer  
725 Institute, Amsterdam, the Netherlands

726  
727 \*shared first authors  
728 # corresponding authors: [w.zwart@nki.nl](mailto:w.zwart@nki.nl), [a.bergman@nki.nl](mailto:a.bergman@nki.nl)

729

730

731

732

733

734

735

736

## 737 References

- 738 1 Ferlay, J. *et al.* Cancer statistics for the year 2020: An overview. *Int J Cancer* (2021).  
739 <https://doi.org/10.1002/ijc.33588>
- 740 2 Mottet, N. *et al.* EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1:  
741 Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol* **79**, 243-262 (2021).  
742 <https://doi.org/10.1016/j.eururo.2020.09.042>
- 743 3 Freedland, S. J. *et al.* Risk of prostate cancer-specific mortality following biochemical recurrence after  
744 radical prostatectomy. *JAMA* **294**, 433-439 (2005). <https://doi.org/10.1001/jama.294.4.433>
- 745 4 Kupelian, P. A., Mahadevan, A., Reddy, C. A., Reuther, A. M. & Klein, E. A. Use of different definitions  
746 of biochemical failure after external beam radiotherapy changes conclusions about relative treatment  
747 efficacy for localized prostate cancer. *Urology* **68**, 593-598 (2006).  
748 <https://doi.org/10.1016/j.urology.2006.03.075>
- 749 5 Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. A. & Catalona, W. J. Cancer progression and survival  
750 rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term  
751 results. *J Urol* **172**, 910-914 (2004). <https://doi.org/10.1097/01.ju.0000134888.22332.bb>
- 752 6 Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress  
753 in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* **6**,  
754 76-85 (2009). <https://doi.org/10.1038/ncpuro1296>
- 755 7 van Royen, M. E. *et al.* Compartmentalization of androgen receptor protein-protein interactions in  
756 living cells. *J Cell Biol* **177**, 63-72 (2007). <https://doi.org/10.1083/jcb.200609178>
- 757 8 Lupien, M. *et al.* FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific  
758 transcription. *Cell* **132**, 958-970 (2008). <https://doi.org/10.1016/j.cell.2008.01.018>

- 759 9 Wang, Q. *et al.* Androgen receptor regulates a distinct transcription program in androgen-independent  
760 prostate cancer. *Cell* **138**, 245-256 (2009). <https://doi.org/10.1016/j.cell.2009.04.056>
- 761 10 Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide  
762 predictions. *Nat Rev Genet* **15**, 272-286 (2014). <https://doi.org/10.1038/nrg3682>
- 763 11 Kim, T. K. & Shiekhhattar, R. Architectural and Functional Commonalities between Enhancers and  
764 Promoters. *Cell* **162**, 948-959 (2015). <https://doi.org/10.1016/j.cell.2015.08.008>
- 765 12 Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl*  
766 *J Med* **367**, 1187-1197 (2012). <https://doi.org/10.1056/NEJMoa1207506>
- 767 13 Beer, T. M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* **371**,  
768 424-433 (2014). <https://doi.org/10.1056/NEJMoa1405095>
- 769 14 Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. & Prekovic, S. Enzalutamide therapy for  
770 advanced prostate cancer: efficacy, resistance and beyond. *Endocr Relat Cancer* **26**, R31-R52 (2018).  
771 <https://doi.org/10.1530/ERC-18-0289>
- 772 15 Mazrooei, P. *et al.* Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants  
773 on Master Transcription Regulators in Primary Prostate Tumors. *Cancer Cell* **36**, 674-689 e676 (2019).  
774 <https://doi.org/10.1016/j.ccell.2019.10.005>
- 775 16 Pomerantz, M. M. *et al.* The androgen receptor cistrome is extensively reprogrammed in human  
776 prostate tumorigenesis. *Nat Genet* **47**, 1346-1351 (2015). <https://doi.org/10.1038/ng.3419>
- 777 17 Stelloo, S. *et al.* Androgen receptor profiling predicts prostate cancer outcome. *EMBO Mol Med* **7**,  
778 1450-1464 (2015). <https://doi.org/10.15252/emmm.201505424>
- 779 18 Pomerantz, M. M. *et al.* Prostate cancer reactivates developmental epigenomic programs during  
780 metastatic progression. *Nat Genet* **52**, 790-799 (2020). <https://doi.org/10.1038/s41588-020-0664-8>
- 781 19 Scher, H. I. *et al.* Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated  
782 Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol* **34**, 1402-  
783 1418 (2016). <https://doi.org/10.1200/JCO.2015.64.2702>
- 784 20 Schwartz, L. H. *et al.* RECIST 1.1-Update and clarification: From the RECIST committee. *Eur J Cancer* **62**,  
785 132-137 (2016). <https://doi.org/10.1016/j.ejca.2016.03.081>
- 786 21 Singh, A. A. *et al.* Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.  
787 *Life Sci Alliance* **2**, e201800115 (2019). <https://doi.org/10.26508/lsa.201800115>
- 788 22 Severson, T. M. *et al.* Epigenetic and transcriptional analysis reveals a core transcriptional program  
789 conserved in clonal prostate cancer metastases. *Mol Oncol* **15**, 1942-1955 (2021).  
790 <https://doi.org/10.1002/1878-0261.12923>
- 791 23 Severson, T. M. *et al.* Characterizing steroid hormone receptor chromatin binding landscapes in male  
792 and female breast cancer. *Nat Commun* **9**, 482 (2018). <https://doi.org/10.1038/s41467-018-02856-2>
- 793 24 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079 (2009).  
794 <https://doi.org/10.1093/bioinformatics/btp352>
- 795 25 Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008).  
796 <https://doi.org/10.1186/gb-2008-9-9-r137>
- 797 26 Marinov, G. K., Kundaje, A., Park, P. J. & Wold, B. J. Large-scale quality analysis of published ChIP-seq  
798 data. *G3 (Bethesda)* **4**, 209-223 (2014). <https://doi.org/10.1534/g3.113.008680>
- 799 27 Ramirez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic*  
800 *Acids Res* **44**, W160-165 (2016). <https://doi.org/10.1093/nar/gkw257>
- 801 28 Lopez-Delisle, L. *et al.* pyGenomeTracks: reproducible plots for multivariate genomic datasets.  
802 *Bioinformatics* **37**, 422-423 (2021). <https://doi.org/10.1093/bioinformatics/btaa692>
- 803 29 Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation,  
804 comparison and visualization. *Bioinformatics* **31**, 2382-2383 (2015).  
805 <https://doi.org/10.1093/bioinformatics/btv145>
- 806 30 Stelloo, S. *et al.* Integrative epigenetic taxonomy of primary prostate cancer. *Nat Commun* **9**, 4900  
807 (2018). <https://doi.org/10.1038/s41467-018-07270-2>
- 808 31 Handle, F. *et al.* Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. *Sci Rep* **9**,  
809 13786 (2019). <https://doi.org/10.1038/s41598-019-50220-1>

- 810 32 Taavitsainen, S. *et al.* Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells  
811 associated with prostate cancer relapse. *Nat Commun* **12**, 5307 (2021).  
812 <https://doi.org/10.1038/s41467-021-25624-1>
- 813 33 Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e3529 (2021).  
814 <https://doi.org/10.1016/j.cell.2021.04.048>
- 815 34 Zheng, R. *et al.* Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis.  
816 *Nucleic Acids Res* **47**, D729-D735 (2019). <https://doi.org/10.1093/nar/gky1094>
- 817 35 Layer, R. M. *et al.* GIGGLE: a search engine for large-scale integrated genome analysis. *Nat Methods*  
818 **15**, 123-126 (2018). <https://doi.org/10.1038/nmeth.4556>
- 819 36 Nguyen, H. M. *et al.* LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular  
820 Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics.  
821 *Prostate* **77**, 654-671 (2017). <https://doi.org/10.1002/pros.23313>
- 822 37 Bishop, J. L. *et al.* The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed  
823 Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discov* **7**, 54-71 (2017).  
824 <https://doi.org/10.1158/2159-8290.CD-15-1263>
- 825 38 Culig, Z. *et al.* Switch from antagonist to agonist of the androgen receptor bicalutamide is associated  
826 with prostate tumour progression in a new model system. *Br J Cancer* **81**, 242-251 (1999).  
827 <https://doi.org/10.1038/sj.bjc.6690684>
- 828 39 Kim, S. *et al.* PEG10 is associated with treatment-induced neuroendocrine prostate cancer. *J Mol*  
829 *Endocrinol* **63**, 39-49 (2019). <https://doi.org/10.1530/JME-18-0226>
- 830 40 Kregel, S. *et al.* Acquired resistance to the second-generation androgen receptor antagonist  
831 enzalutamide in castration-resistant prostate cancer. *Oncotarget* **7**, 26259-26274 (2016).  
832 <https://doi.org/10.18632/oncotarget.8456>
- 833 41 Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput  
834 screening data analysis. *Nat Biotechnol* **24**, 167-175 (2006). <https://doi.org/10.1038/nbt1186>
- 835 42 Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination  
836 synergies. *Nucleic Acids Res* **48**, W488-W493 (2020). <https://doi.org/10.1093/nar/gkaa216>
- 837 43 Stelloo, S. *et al.* Endogenous androgen receptor proteomic profiling reveals genomic subcomplex  
838 involved in prostate tumorigenesis. *Oncogene* **37**, 313-322 (2018).  
839 <https://doi.org/10.1038/onc.2017.330>
- 840 44 Ross-Innes, C. S. *et al.* Differential oestrogen receptor binding is associated with clinical outcome in  
841 breast cancer. *Nature* **481**, 389-393 (2012). <https://doi.org/10.1038/nature10730>
- 842 45 Mei, S. *et al.* Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in  
843 human and mouse. *Nucleic Acids Res* **45**, D658-D662 (2017). <https://doi.org/10.1093/nar/gkw983>
- 844 46 Shukla, S. *et al.* Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer  
845 Mediates Castration Resistance. *Cancer Cell* **32**, 792-806 e797 (2017).  
846 <https://doi.org/10.1016/j.ccell.2017.10.008>
- 847 47 Li, J. *et al.* Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide  
848 resistant prostate cancer. *Elife* **6** (2017). <https://doi.org/10.7554/eLife.20183>
- 849 48 Shah, N. *et al.* Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives  
850 antiandrogen resistance in prostate cancer. *Elife* **6** (2017). <https://doi.org/10.7554/eLife.27861>
- 851 49 Puhr, M. *et al.* The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a  
852 Target for Improved Antiandrogen Therapy. *Clin Cancer Res* **24**, 927-938 (2018).  
853 <https://doi.org/10.1158/1078-0432.CCR-17-0989>
- 854 50 Jones, D. *et al.* FOXA1 regulates androgen receptor variant activity in models of castrate-resistant  
855 prostate cancer. *Oncotarget* **6**, 29782-29794 (2015). <https://doi.org/10.18632/oncotarget.4927>
- 856 51 Chaytor, L. *et al.* The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled  
857 by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. *Mol Cancer Res*  
858 **17**, 1264-1278 (2019). <https://doi.org/10.1158/1541-7786.MCR-18-1231>
- 859 52 McLeod, A. B. *et al.* Validation of histone deacetylase 3 as a therapeutic target in castration-resistant  
860 prostate cancer. *Prostate* **78**, 266-277 (2018). <https://doi.org/10.1002/pros.23467>

- 861 53 Malik, R. *et al.* Targeting the MLL complex in castration-resistant prostate cancer. *Nat Med* **21**, 344-  
862 352 (2015). <https://doi.org/10.1038/nm.3830>
- 863 54 Liu, J. *et al.* Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted  
864 Benzamide Zinc Binding Group. *ACS Med Chem Lett* **11**, 2476-2483 (2020).  
865 <https://doi.org/10.1021/acsmchemlett.0c00462>
- 866 55 Olsen, E. A. *et al.* Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or  
867 treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* **25**, 3109-3115 (2007).  
868 <https://doi.org/10.1200/JCO.2006.10.2434>
- 869 56 Butler, L. M. *et al.* Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses  
870 the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* **60**, 5165-5170 (2000).
- 871 57 Marrocco, D. L. *et al.* Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor  
872 expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer  
873 cell proliferation. *Mol Cancer Ther* **6**, 51-60 (2007). <https://doi.org/10.1158/1535-7163.MCT-06-0144>
- 874 58 Biersack, B., Nitzsche, B. & Hopfner, M. HDAC inhibitors with potential to overcome drug resistance in  
875 castration-resistant prostate cancer. *Cancer Drug Resist* **5**, 64-79 (2022).  
876 <https://doi.org/10.20517/cdr.2021.105>
- 877 59 Morova, T. *et al.* Androgen receptor-binding sites are highly mutated in prostate cancer. *Nat Commun*  
878 **11**, 832 (2020). <https://doi.org/10.1038/s41467-020-14644-y>
- 879 60 Zhou, S. *et al.* Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate  
880 cancer. *Nat Commun* **11**, 441 (2020). <https://doi.org/10.1038/s41467-020-14318-9>
- 881 61 Takeda, D. Y. *et al.* A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver  
882 in Advanced Prostate Cancer. *Cell* **174**, 422-432 e413 (2018).  
883 <https://doi.org/10.1016/j.cell.2018.05.037>
- 884 62 Quigley, D. A. *et al.* Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*  
885 **174**, 758-769 e759 (2018). <https://doi.org/10.1016/j.cell.2018.06.039>
- 886 63 Prekovic, S. *et al.* The Effect of F877L and T878A Mutations on Androgen Receptor Response to  
887 Enzalutamide. *Mol Cancer Ther* **15**, 1702-1712 (2016). <https://doi.org/10.1158/1535-7163.MCT-15-0892>
- 888
- 889 64 Korpala, M. *et al.* An F876L mutation in androgen receptor confers genetic and phenotypic resistance  
890 to MDV3100 (enzalutamide). *Cancer Discov* **3**, 1030-1043 (2013). <https://doi.org/10.1158/2159-8290.CD-13-0142>
- 891
- 892 65 Sun, C. *et al.* Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell  
893 survival. *Oncogene* **25**, 3905-3913 (2006). <https://doi.org/10.1038/sj.onc.1209424>
- 894 66 Park, S. H. *et al.* Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin  
895 complex in prostate cancer. *Sci Adv* **7** (2021). <https://doi.org/10.1126/sciadv.abe2261>
- 896 67 Gao, S. *et al.* Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate  
897 cancer. *Nat Genet* **52**, 1011-1017 (2020). <https://doi.org/10.1038/s41588-020-0681-7>
- 898 68 Welsbie, D. S. *et al.* Histone deacetylases are required for androgen receptor function in hormone-  
899 sensitive and castrate-resistant prostate cancer. *Cancer Res* **69**, 958-966 (2009).  
900 <https://doi.org/10.1158/0008-5472.CAN-08-2216>
- 901 69 Gray, J. E. *et al.* Phase I/II Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small  
902 Cell Lung Cancer. *Clin Cancer Res* **25**, 6623-6632 (2019). <https://doi.org/10.1158/1078-0432.CCR-19-1305>
- 903
- 904 70 Bradley, D. *et al.* Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy  
905 (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the  
906 Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2  
907 Consortium. *Cancer* **115**, 5541-5549 (2009). <https://doi.org/10.1002/cncr.24597>
- 908 71 Ferrari, A. C. *et al.* Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in  
909 Castration-Resistant Prostate Cancer. *Clin Cancer Res* **25**, 52-63 (2019). <https://doi.org/10.1158/1078-0432.CCR-18-1589>
- 910
- 911

912

913

## 914 **Figure Legends**

### 915 **Figure 1: Clinical trial design and ChIP-seq data collection**

916 A. Setup of the clinical trial. Patients with mCRPC are enrolled in the study, and an  
917 imaging-guided biopsy is taken prior to onset of enzalutamide treatment. One patient  
918 in the study was treated with abiraterone.

919 B. Correlation heatmap of ChIP-seq data (50kb bins across the genome, Pearson  
920 correlation) for H3K27ac, AR and FOXA1 among all mCRPC samples (n=40). Colors  
921 bars indicate ChIP factors: AR (light blue), FOXA1 (light green) and H3K27ac (dark  
922 green), tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone  
923 (dark green), treatment: abiraterone (Abi, salmon)) and enzalutamide (ENZA,  
924 brown)), condition of the sample: pre-treatment (purple) and post-treatment (orange),  
925 and treatment response: non-responder (dark purple), responder (pink), intermediate  
926 (blue) and unknown (black outline).

927 C. Snapshot of H3K27ac ChIP-seq (n=28) in different treatment response groups:  
928 responders (pink), non-responders (purple), unknown ((unk.), black outline) and  
929 intermediate (blue). The read counts (left) and genomic coordinates (bottom) are  
930 indicated.

931 D. Principal Component Analysis using normalized read counts in all peaks in H3K27ac  
932 ChIP-seq data (n=73039) from all samples (n=28). Samples labeled according to  
933 responders (pink), non-responders (purple), intermediate (blue) or unknown (white).

934

### 935 **Figure 2: Distinct H3K27ac profiles stratify mCRPC patients on response to AR** 936 **inhibition**

- 937 A. Differentially enriched regions from H3K27ac ChIP-seq data visualized by volcano  
938 plot (n=73039). Regions marked by blue dots were significant (DiffBind DESeq2 two-  
939 tailed adjusted p-value  $\leq 0.05$ ,  $\log_{2}FC \geq \text{abs}(2)$ ) (n=848); all other regions are shown  
940 with hexbin density to avoid over-plotting (n=72191). Each data point density tile  
941 (hexagon) represents density of data within the tile from low (light grey) to high (black).
- 942 B. Heatmap showing normalized read count of H3K27ac data in significantly differentially  
943 bound regions (DiffBind DESeq2 two-tailed adjusted p-value  $\leq 0.05$ ,  $\log_{2}FC \geq \text{abs}(2)$ )  
944 (n=848) in responder (n=8) and non-responder samples (n=9). Colors bars indicate  
945 tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone (dark  
946 green), treatment: abiraterone (Abi, salmon) and enzalutamide (ENZA, brown)),  
947 condition of the sample: pre-treatment (purple) and post-treatment (orange) and  
948 treatment response: non-responder (dark purple) and responder (pink).
- 949 C. Individual snapshot of H3K27ac enriched differently in 3 responder patients (pink) and  
950 3 non-responder patients (purple) as examples. The read counts and genomic  
951 coordinates are indicated (top right and bottom, respectively).
- 952 D. Average H3K27ac read count profiles of all merged data for responder patients (pink,  
953 n=8) and all merged non-responder patients (purple, n=9) at the 657 non-responder  
954 enriched sites ( $\pm 5$  kb from the peak center). Shading indicates standard-error of the  
955 data.

956

957 **Figure 3: mCRPC PDX validations of resistance-associated H2K27ac regions**

- 958 A. Overview of the PDX models setup. Prostate cancer samples from mCRPC patients  
959 were obtained and implanted into the mouse to establish PDXs. These PDXs were  
960 characterized previously with their response to castration by the change of tumor  
961 volume.



- 962 B. Heatmap depicting raw read counts of H3K27ac ChIP-seq signal from PDX samples  
963 at the non-responder enriched 657 H3K27ac regions, identified from the mCRPC  
964 patient samples ( $\pm 5$  kb from the peak center ).
- 965 C. Average H3K27ac read count profiles of all PDX merged data for samples with weak  
966 (grey, n=8) and strong (black, n=7) signal in the non-responder 657 H3K27ac regions.  
967 ( $\pm 5$  kb from the peak center). Shading indicates standard-error of the data.
- 968 D. Box plots depicting doubling time of PDX models estimated using exponential  
969 (Malthusian) growth model (y-axis) by group (x-axis). The central mark indicates the  
970 median, and the bottom and top edges of the box indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles,  
971 respectively. The maximum whisker lengths are specified as 1.5 times the interquartile  
972 range. All individual values are depicted as circles colored by PDX model (strong  
973 H3K27ac – Castration: n=57, strong H3K27ac – Control: n=45, weak H3K27ac –  
974 Castration: n=71, weak H3K27ac – Control: n=73). Table below indicates the p-values  
975 obtained for one-way ANOVA followed by Tukey HSD test for all combinations.
- 976 E. Polar plot reporting the  $-10 \cdot \log_{10}(\text{p-values})$  (Fisher's exact test) of gene overlap  
977 enrichment tests between genes associated with H3K27ac non-responder regions and  
978 LNCaP scRNA-seq cluster marker genes. Color indicates strength of significance from  
979 low (pink) to high (red).
- 980 F. Uniform manifold approximation and projection (UMAP) visualization showing the  
981 average gene expression score of genes associated with H3K27ac non-responder  
982 regions in the parental LNCaP (left) and the ENZA-Resistant, RES-B (right) single cells.  
983 Original scRNA-seq clusters (0-12) are superimposed on each plot.

984  
985 **Figure 4: Characterization of the non-responder enriched H3K27ac sites reveals**  
986 **drivers of resistance**

- 987 A. Enrichment analysis to determine significant overlap of 657 H3K27ac non-responder  
988 sites with publicly available ChIP-seq data for factors previously studied in prostate  
989 cancer cell lines (n=863). Graph shows median enrichment score for each factor  
990 (GIGGLE combo score, indicating low to high significant enrichment score (Fisher's  
991 exact two-tailed test and odds-ratio)). Factors are ordered by highest score  
992 (enrichment) in the dataset with text shown in those with median enrichment score >  
993 100.
- 994 B. Average FOXA1 read count profiles of merged data, at the 657 non-responder  
995 enriched H3K27ac sites ( $\pm 5$  kb from the peak center), comparing responders (pink,  
996 n=8) and non-responders (purple, n=9). Shading indicates standard-error of the data.
- 997 C. Setup of siRNA screen to identify factors critical of prostate cancer cell line viability,  
998 resistant to androgen ablation or enzalutamide treatment.
- 999 D. Screen results for pooled siRNAs, showing decreased viability of prostate cancer cell  
1000 line models LNCaP-Abl (left), LNCaP-Enz<sup>R</sup> (middle) and LNCaP-16D (right). Cell  
1001 viability was determined by CellTiter-Blue, and data are normalized over siControl.  
1002 Bars indicate mean values  $\pm$  SD (n $\geq$ 2). Adjusted P values (padj) were determined by  
1003 two-sided t-test with multiple testing correction (Benjamini-Hochberg method).  
1004 Statistically significant conditions (padj <0.05) are shown in red.
- 1005 E. siRNA deconvolution experiment, separately analyzing each individual siRNA for the  
1006 11 remaining hits in LNCaP-16D cells on cell viability. Cell viability was determined  
1007 by CellTiter-Blue and data are normalized over siControl. Bars indicate mean values  
1008  $\pm$  SD (n $\geq$ 3). Adjusted P values determined as above. Statistically significant conditions  
1009 (padj <0.05) are shown in red.
- 1010 F. Enzalutamide-vorinostat drug synergy analyses for LNCaP (top) and LNCaP-16D  
1011 (bottom) based on viability experiments performed after 5 days of treatment.

1012 Vorinostat and enzalutamide (ENZA) concentrations in nM on the x- and y-axis,  
1013 respectively. Synergy determined using the HSA model (score >10 indicates synergy  
1014 with regions of maximal synergy outlined in white). Graphs representative for 4  
1015 biological replicates.

1016 G. (Left) Experimental setup of tumor explant studies. Tumor samples are removed from  
1017 the animals, and exposed *ex vivo* to increasing concentrations of enzalutamide and  
1018 vorinostat and assessed for viability. (Right) Drug synergy representation for mCRPC  
1019 PDX explant LuCaP 23.1. Synergy determined using the HSA model (score > 10  
1020 indicates synergy with regions of maximal synergy outlined in white).

1021

1022 **Supplemental information**

1023 **Supplemental File 1:**

1024 Contains 9 Supplementary Figures and 4 Supplementary Tables


1025

1026 **Supplemental File 2:**


1027 Contains additional clinical trial information

# Figure 1: Clinical trial design and ChIP-seq data collection


A



B



C



D






Figure 2: Differential binding analysis of H3K27ac data for response status


A



B



C




D




Figure 3: mCRPC PDX and scRNA-seq validations of resistance-associated H3K27ac regions


A




B




C



D



E



F




Figure 4: Characterization of the non-responder enriched H3K27ac sites reveals drivers of resistance

